Damodar S
J Assoc Physicians India. 2015 Mar;63(3 Suppl):16-20.
Immunosuppressive therapy is the standard of care in aplastic anaemia in younger patients who do not have a matched sibling donor, and also in adults and older patients. Hence, a large population of patients with aplastic anaemia undergo this treatment. In patients who have responded to the first course of ATG, and have had a relapse, a second course of ATG can be administered with reasonable response rates. Response rates to first course of ATG vary from 50-85% in both children and adult. Indian data also suggests similar response rates.
免疫抑制疗法是没有匹配同胞供体的年轻再生障碍性贫血患者以及成人和老年患者的标准治疗方法。因此，大量再生障碍性贫血患者接受这种治疗。对于对第一疗程抗胸腺细胞球蛋白（ATG）有反应但复发的患者，可以给予第二疗程的ATG，且缓解率合理。儿童和成人对第一疗程ATG的缓解率在50%至85%之间。印度的数据也表明有类似的缓解率。
